return to news
  1. Sai Life Sciences IPO opens December 11, sets price band at ₹522-549 per share

Market News

Sai Life Sciences IPO opens December 11, sets price band at ₹522-549 per share

PTI.jpg

3 min read | Updated on December 06, 2024, 12:57 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Sai Life Sciences, backed by TPG Capital, is set to launch its ₹3,043 crore IPO on December 11, 2024, with a price band of ₹522-549 per share. The offering includes a fresh issue of ₹950 crore and an Offer For Sale (OFS) of 3.81 crore shares by promoters and investors, including TPG Asia VII and HBM Private Equity India.

The initial share sale will conclude on December 13, and the bidding for the anchor portion will open for a day on December 10, the company announced.

The initial share sale will conclude on December 13, and the bidding for the anchor portion will open for a day on December 10, the company announced.

Private equity major TPG Capital-backed Sai Life Sciences on Friday said it has fixed a price band of ₹522-549 per equity share for its ₹3,043 crore Initial Public Offering (IPO) that opens for public subscription on December 11.

The initial share sale will conclude on December 13, and the bidding for the anchor portion will open for a day on December 10, the company announced.

The IPO is a combination of a fresh issue of equity shares worth up to ₹950 crore and an Offer For Sale (OFS) of up to 3.81 crore equity shares by a promoter, investor shareholders and other shareholders, according to the Red Herring Prospectus (RHP).

Under the OFS, one of the promoter entities -- Sai Quest Syn Pvt Ltd -- and investor shareholders -- TPG Asia VII SF Pte Ltd, HBM Private Equity India -- will offload their respective stakes.

Bharathi Srivari, Anita Rudraraju Nandyala, Raju Penmasta, Dirk Walter Sartor, Jagdish Viswanath Dore, Rajagopal Srirama Tatta and K Pandu Ranga Raju were the other selling shareholders who will also divest their stakes in the company.

At the upper end of the price band, the company is going to fetch around ₹3,042.62 crore from the IPO.

Earlier, the Hyderabad-based Sai Life Sciences had filed its IPO papers with the Securities and Exchange Board of India (SEBI) in July 2024 and obtained the markets regulator's approval in November, to float the initial share sale.

Of the IPO proceeds, funds to the tune of ₹720 crore will be used for debt payment and a portion will be used for corporate general purposes.

Investors can bid for a minimum of 27 equity shares and in multiples thereafter.

Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule New Chemical Entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.

During the six-month ended September 2024, Sai Life Sciences reported a total income of ₹693.35 crore against ₹656.8 crore a year ago. It posted a net profit for the six months at ₹28.01 crore as compared to a loss of ₹12.92 crore last year.

Kotak Mahindra Capital Company Ltd, IIFL Capital Services Ltd (formerly IIFL Securities Ltd), Jefferies India and Morgan Stanley India Company are the book running lead managers, while KFin Technologies is the registrar for the IPO.

The company's shares are proposed to be listed on the BSE and National Stock Exchange (NSE).

About The Author

PTI.jpg
Press Trust of India (PTI) is India's premier news agency.

Next Story